2CBCB-NBOMe, or NBOMe-TCB-2, is a serotonin receptor modulator and cyclized phenethylamine. It is the NBOMe derivative of the psychedelic drug TCB-2 (2C-BCB).
2CBCB-NBOMe acts as a potent and selective agonist of the serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptors, with an affinity (K<sub>i</sub>) of 0.27nM at the human serotonin 5-HT<sub>2A</sub> receptor, similar to that of other drugs such as TCB-2, 25I-NBOMe, and Bromo-DragonFLY.
2CB2CB-NBOMe was first described in the scientific literature by the lab of David E. Nichols and colleagues in 2007. It was part of an ongoing research program focused on mapping of the specific amino acid residues responsible for ligand binding to the serotonin 5-HT<sub>2A</sub> receptor.
2CBCB-NBOMe is not a controlled substance in Canada as of 2025.
2CBCB-NBOMe is a controlled substance in Vermont as of January 2016.